Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 39.70 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 14.63 | Oscillator | Buy |
| Williams %R (14) | -86.67 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.12 (Hist -0.06) | Oscillator | Strong Sell |
| Average Directional Index (14) | 25.20 (+DI 10.3 / -DI 22.1) | Trend | Strong Sell |
Current price $3.44
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 27, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 22, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Feb 3, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Dec 12, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Dec 3, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Oct 3, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 19, 24 |
| EMA 20 | 3.71 | MA | Strong Sell |
| SMA 20 | 3.82 | MA | Strong Sell |
| EMA 50 | 3.75 | MA | Strong Sell |
| SMA 50 | 3.80 | MA | Strong Sell |
| SMA 200 | 3.92 | MA | Strong Sell |
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| Sep 11, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jun 4, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
TTM vs. 5-year historical average (annual ratios)
| Metric | BCTX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.3x | -13.6x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.3x | EPS est. -11.45 | In line |
| Price / Book | 1.0x | -32.5x | Discount |
| Price / Sales | — | — | n/a |
| EV / EBITDA | -0.7x | -18.9x | Discount |
| Return on equity | -147.9% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.00 | 0.00 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -3.85 | Distress |
Discounted cash flow model
Stock news · updated daily
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announced the presentation of clinical biomarker findings from a prospective pooled analysis of patients with metastatic breast cancer (“MBC”) treated with immune based therapies including the BriaCell regimen at the European Society for Medical Oncology (“ESMO”) Congress 2026, taking place October 23-27, 2026 in Madrid, Spain. The data shown is pooled from several studies including BriaCell's Phase 1/2 Bria-IMT study.
| 8-K | Mar 31, 2026 | 2026-03-31 16:10:13 | View |
| 10-Q | Mar 10, 2026 | 2026-03-10 17:08:51 | View |
| 8-K | Mar 9, 2026 | 2026-03-09 16:52:46 | View |
| 25-NSE | Feb 26, 2026 | 2026-02-26 14:40:34 | View |
| 8-K | Feb 20, 2026 | 2026-02-20 16:00:33 | View |
| DEF 14A | Feb 12, 2026 | 2026-02-12 16:00:22 | View |
Proxy statement (DEF 14A) disclosures
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced that four abstracts featuring preclinical research from their respective immunotherapy programs have been selected for poster presentations at the Society for Immunotherapy of Cancer (SITC) 41th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ. The presentations will feature BriaCell's personalized off-the-shelf immunotherapy, Bria-OTS+™ and BriaPro's research on tumor-targeted checkpoint inhibitors, soluble CD80 (BP-80), and engineered CD80 variants.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jun 9, 2026 | — | -0.99 | — | — |
| Mar 10, 2026 | -4.84 | -2.58 | Beat 46.7% | — |
| Dec 11, 2025 | -3.28 | -4.35 | Miss -32.6% | — |
| Oct 27, 2025 | -12.11 | -10.49 | Beat 13.4% | — |
| Jun 16, 2025 | -17.60 | -1.64 | Beat 90.7% | — |
| Mar 12, 2025 | -19.40 | -23.30 | Miss -20.1% | — |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| May 14, 24 | Lustig Marc | director, 10 percent owner: | P-Purchase | 902,935 @ $2.22 | $2.00M |
| May 14, 24 | Lustig Marc | director, 10 percent owner: | P-Purchase | 902,935 @ $2.11 | $1.91M |
| Dec 28, 22 | Bondarenko Jamieson | officer: Chairman | P-Purchase | 28,000 @ $4.58 | $128.2K |
| Dec 23, 22 | Williams William V. | officer: President, CEO | P-Purchase | 2,530 @ $1.94 | $4.91K |
| Dec 20, 22 | Bondarenko Jamieson | director | P-Purchase | 22,000 @ $5.35 | $117.7K |
| Aug 1, 22 | Bondarenko Jamieson | director | D | 0 | — |
| Mar 29, 21 | Bondarenko Jamieson | director | D | 150,000 @ $4.24 | $636.0K |
| Aug 1, 22 | Bondarenko Jamieson | director | D | 250,000 @ $8.47 | $2.12M |